12 citations
,
June 2020 in “The anatomical record” miR-203a-3p helps hair follicle stem cells become specialized by targeting Smad1.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
55 citations
,
June 2014 in “Nature Communications” Tcf3 helps cells move and heal wounds by controlling lipocalin 2.
May 2023 in “Journal of drugs in dermatology” Most transgender patients getting laser hair removal before gender-affirming surgery are already on hormone therapy, which might affect the hair removal process.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
34 citations
,
July 2011 in “International journal of pharmaceutics” Ion-paired risedronate significantly increases skin penetration without irritation compared to risedronate alone.
October 2025 in “International Journal of Dermatology” GLP-1 receptor agonists may cause hair loss, but regrowth is rare.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
38 citations
,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
May 2024 in “Reactions weekly” 3 citations
,
May 2018 in “Psychiatry and Clinical Psychopharmacology” N-acetylcysteine may help treat trichotillomania.
37 citations
,
October 2006 in “Steroids” New sulfur-containing steroid analogs show promise for more targeted medical treatments.
24 citations
,
November 2015 in “Frontiers in Genetics” Nitroxide drugs can safely and effectively treat age-related diseases like macular degeneration and cardiovascular issues.
6 citations
,
July 2016 in “Doklady Biochemistry and Biophysics” GD-23 reduces anxiety by relying on neurosteroid production.
140 citations
,
February 2014 in “Neuron” Delta opioid receptors help regulate touch sensation by reducing neurotransmitter release in the spinal cord.
37 citations
,
January 2011 in “Annals of Dermatology” ALA-photodynamic therapy helps reduce acne by causing acne cell death and lowering certain skin protein levels.
The document's conclusion cannot be provided because the document is not available or cannot be read.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
4 citations
,
March 2019 in “Journal of Pure and Applied Microbiology” A 940nm laser effectively reduces inflammation in rat joints.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
August 2023 in “Journal of Cosmetic Dermatology” Exosomes from hair papilla cells and the Chinese medicine Liao Tuo Fang can potentially promote hair growth and could be used to develop hair growth drugs.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2025 in “Radboud University Press eBooks” AHR ligands could treat inflammatory skin diseases.
74 citations
,
January 2011 in “Reproductive Biology and Endocrinology” Testosterone therapy can improve hormone levels and quality of life in men with morphine-induced hormone issues.
8 citations
,
January 2011 in “Korean Journal of Andrology” The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.